Dr. Merdad Parsey
Chief medical officer,
Parsey joined the pharmaceutical company in 2019 from Genentech. He oversees global clinical development and medical affairs, including clinical trials. The company’s antirviral drug remdesivir, originally developed for hepatitis C and Ebola, showed early promise in speeding recovery for patients with COVID-19. A National Institutes of Health-funded study published in late May detailed some of the drug’s limitations, mainly that it worked best on patients who needed oxygen supplementation, not a ventilator.